For hospital systems.

Hospital systems operating across multiple sites in the countries we serve, particularly in the United Arab Emirates, the Kingdom of Saudi Arabia, and India, face a coordination challenge that case-by-case specialty access does not solve well. A system that runs specialty oncology in three hospitals, rare-disease infusion in a dedicated clinic, and cross-border access through an informal prescriber network is usually paying three prices for the same capability and accepting three different levels of chain-of-custody risk. A single institutional relationship with Reserve Meds replaces that patchwork with one coordinator, one SOP, and one accountable channel.

What changes for a system

A system-level engagement collapses the intake surface. A single institutional case-coordination lead on our side handles every case that originates anywhere in the system. The receiving SOP is standardized across sites so that a shipment landing at one hospital follows the same incoming inspection as a shipment landing at another. Documentation is pre-approved, which means the prescription format, the medical-necessity letter template, and the patient consent form are each vetted by the system's compliance function once, rather than case by case. Invoicing consolidates into a single monthly or quarterly cycle, with per-case and per-site detail preserved for the system's internal accounting. Outcome reporting rolls up to a system-level view that supports board-level oversight of specialty access.

Typical engagement shape

A typical hospital-system engagement opens with an exploratory call and a pilot of two to five cases across a representative subset of the system's sites. During the pilot, both sides work out the practical interfaces: how prescriptions route from the prescriber to our intake, how the receiving pharmacy at each site accepts and reconciles shipments, how the system's compliance function reviews documentation, and how escalations are handled. The pilot is typically completed in eight to twelve weeks, at which point the partnership moves to a standing master services agreement. Under the MSA, case volumes can scale up significantly without a re-negotiation, because the interfaces are now understood on both sides.

Clinical governance at the system level

Hospital systems that operate their own clinical governance over specialty therapy selection typically want to understand where our clinical review sits relative to their own. The honest answer is that our review is a pharmacy-level review designed to catch label, evidence, patient-fit, and administrability issues before product moves; it is not a substitute for the system's clinical governance over therapy selection. A system's pharmacy and therapeutics committee remains the appropriate body to govern which therapies the system will administer. Our review catches the issues that a specialty pharmacy would catch, and we flag them to the prescribing physician and the system's pharmacy leadership for resolution. Where a system wants us to integrate our review flags into its own clinical-governance workflow, we configure the handoff during the pilot.

Receiving SOP standardization

One of the highest-value operational shifts in a hospital-system engagement is standardizing the receiving SOP across sites. A system typically has some sites with mature specialty receiving and some sites where specialty receiving is newer or less well-documented. The pilot period is an opportunity to bring the less-mature sites up to the system's best-practice standard, using our receiving protocol and receiving checklist as starting points. The result is a system-wide receiving posture that is both consistent and documented, which reduces audit exposure and supports the system's accreditation workflows.

Pharmacovigilance at the system level

Adverse events reported through a system's own pharmacovigilance channels, where those events relate to therapies coordinated by us, are reconciled with our own pharmacovigilance routing. The result is a single, auditable record of adverse events across the system's specialty-access cases, available to support the system's internal quality reporting and any regulator-facing filings. Our pharmacovigilance team is available to the system's quality leadership on a direct line; for urgent adverse event routing, the email is [email protected].

Data handling and privacy

Patient health information that moves between the system and us is handled under the system's own data-handling framework and under our HIPAA, GDPR, and destination-specific privacy frameworks. Where the system operates under a specific data-handling regime, including UAE DHA, India DPDP, or KSA PDPL requirements, we configure our data flows to meet the higher of the applicable standards. We sign the data processing agreement the system requires; we do not expect to dictate the privacy document.

Commercial structure

The commercial structure of a hospital-system engagement is documented in the master services agreement. The coordination-fee schedule is pre-negotiated; the drug and logistics costs flow through as documented line items per case; the system's payment terms are set in the MSA. We do not offer volume discounts that would implicate anti-kickback rules in the system's jurisdictions; instead, operational efficiencies gained from scale show up as reduced coordination time on large cases and as lower per-case documentation cost, both of which are reflected in the fee schedule. For more on our pricing posture, see how we think about pricing.

Why a system would choose us

The reasons we tend to hear from systems that have chosen a formal engagement with us are consistent. They have experienced a chain-of-custody gap with a previous coordinator and want a DSCSA-serialized US-sourced supply chain. They have experienced opaque pricing and want a documented flow-through model. They have experienced inconsistent receiving across sites and want a standardized SOP. They have experienced poor adverse-event reconciliation and want a pharmacovigilance channel they can audit. Where a system is facing one or more of these concerns, a conversation with us is usually worth an hour. The entry point is [email protected].

Reviewed 2026-04-22 by Reserve Meds’s AI clinical and regulatory review agents. Human pharmacist-in-charge: Altima Care. Next scheduled review: 2026-10-22.